Cytokinetics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytokinetics, Incorporated on February 11, 2025, reporting events occurring on February 10, 2025. The filing addresses corporate governance changes specifically regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation arrangements.
Material Changes
On February 10, 2025, the Board of Directors appointed Robert E. Landry to fill a vacant Board seat as a Class II member, with a term expiring at the 2027 annual meeting. Mr. Landry was also appointed to the Audit Committee. The Board determined Mr. Landry is independent under applicable SEC and Nasdaq standards.
Compensation and Governance Details
- Annual Retainers: $50,000 for Board service and $12,500 for Audit Committee service, pro-rated for partial periods.
- Recurring Equity Grant: Annual grant of restricted stock units (RSUs) and stock options with a grant date fair value of $440,000. Options vest monthly over one year; RSUs vest in one installment after one year.
- Initial Grant: An option to purchase 25,538 shares of common stock with a grant date fair value of $700,000. This grant vests monthly over three years.
- Indemnification: The Company entered into a standard indemnification agreement with Mr. Landry.
Investor Verification Checklist
- Verify the independence status of Robert E. Landry against the Company's Corporate Governance Guidelines.
- Confirm the vesting schedules and fair value assumptions for the $1.14 million total initial equity compensation package.
- Review the Company's proxy statement for the 2027 annual meeting to confirm the expiration of Mr. Landry's Class II term.
- Check for any subsequent filings regarding the actual issuance of the 25,538 stock options.